2U3:FRA
Alcon AG
€59,64
arrow_downward
-2,64%(-1,62) 1D
21 ກ.ລ., 18 ໂມງ 37 ນາທີ 44 ວິນາທີ GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2U3...
Open
€60,88
High
€60,88
Low
€59,62
Mkt. cap
໒໗,໙໘ ຕື້
Avg. vol.
໑໓໙,໐໐
Volume
໑໒໓,໐໐
52-wk high
€79,06
52-wk low
€51,78
No. of employees
໒໕ ພັນ
Open
€60,88
High
€60,88
Low
€59,62
Mkt. cap
໒໗,໙໘ ຕື້
Avg. vol.
໑໓໙,໐໐
Volume
໑໒໓,໐໐
52-wk high
€79,06
52-wk low
€51,78
No. of employees
໒໕ ພັນ
News stories
From sources across the web
Ad-hoc-news.de
·
5 ຊົ່ວໂມງກ່ອນ
Alcon stock trades steady as recent earnings highlight margin and growth dynamics
Ad-hoc-news.de
·
14 ຊົ່ວໂມງກ່ອນ
Alcon stock trades steadily as eye-care leader posts rising revenue and margins
Profile
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
About Alcon AG
CEODavid J. Endicott
Employees25 ພັນ
Founded1945
Headquartersເຈນີວາ, Geneva, ສະວິດເຊີແລນ
SectorMedical device
Websitealcon.com
AI content may include mistakes. Learn more